Table 1.
Patient characteristics
| Characteristics | N (%) |
|---|---|
| All patients | 24 |
| Race | |
| White | 19 (79) |
| African American | 4 (17) |
| Hispanic | 1 (4) |
| Age (years) | |
| Median | 48 |
| Range | 32–69 |
| ECOGa performance status | |
| 0 | 20 (83) |
| 1 | 4 (17) |
| Menopausal status | |
| Pre/peri-menopausal | 15 (63) |
| Post-menopausal | 6 (25) |
| Unknown | 3 (13) |
| Tumor size (cm) | |
| Median | 2.8 |
| Range | 0.6–8.7 |
| Clinical N stage | |
| 0 | 12 (50) |
| 1 | 11 (46) |
| 2 | 1 (4) |
| Clinical stage | |
| I | 1 (4) |
| IIA | 12 (50) |
| IIB | 8 (33) |
| IIIA | 3 (13) |
| Grade | |
| 1 | 0 |
| 2 | 7 (29) |
| 3 | 17 (71) |
| Receptor status | |
| Hormone receptor (+) and HER-2/neu (−) | 7 (29) |
| Hormone receptor (+) and HER-2/neu (+) | 3 (13) |
| Hormone receptor (−) and HER-2/neu (+) | 3 (13) |
| Triple negative | 11 (46) |
aEastern Cooperative Oncology Group (ECOG)